Last 12 months
Inside the activity.
1 purchase rows · 25 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 0 | 6 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 8 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 6 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2017 Filed Jun 21, 2017 16:11 UTC |
BARBERICH TIMOTHY JDirector
|
GrantStock Options (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0000899243-17-016842 · doc4.xml · derivative · entry 1 BARBERICH TIMOTHY J · CIK 0001120355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017, subject to continued service through such dates. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 20:07 UTC |
BOESS CARSTENDirector
|
GrantStock Options (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0000899243-17-016838 · doc4.xml · derivative · entry 1 BOESS CARSTEN · CIK 0001277495 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017, subject to continued service through such dates. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 20:06 UTC |
Phillips Gary M.Director
|
GrantStock Options (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0000899243-17-016836 · doc4.xml · derivative · entry 1 Phillips Gary M. · CIK 0001197795 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017 subject to continued service through such dates. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 20:06 UTC |
HOWES PAUL GDirector
|
GrantStock Options (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0000899243-17-016837 · doc4.xml · derivative · entry 1 HOWES PAUL G · CIK 0001244754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: The stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option grant shall vest in equal quarterly installments at the end of each quarter following June 20, 2017, subject to continued service through such dates. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 20:05 UTC |
CARROLL J MARTINDirector
|
GrantStock Options (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0000899243-17-016835 · doc4.xml · derivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017, subject to continued service through such dates. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 20:05 UTC |
Machado PatrickDirector
|
GrantStock Options (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0000899243-17-016834 · doc4.xml · derivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017, subject to continued service through such dates. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 20:05 UTC |
Spivey Richard N.Director
|
GrantStock Options (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0000899243-17-016833 · doc4.xml · derivative · entry 1 Spivey Richard N. · CIK 0001648385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017, subject to continued service through such dates. Read SEC document |
| January 23, 2017 Filed Jan 24, 2017 21:31 UTC |
SOUTHWELL DAVID PDirector · President and CEO
|
GrantRestricted Stock Units · Derivative | 350,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-001845 · doc4.xml · derivative · entry 2 SOUTHWELL DAVID P · CIK 0001251553 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ITEK common stock. F3 · derivative.exercise_date: The restricted stock units were issued pursuant to the Plan. The restricted stock units shall vest in equal annual installments over 4 years from the date of grant, subject to continued service through such dates. F3 · derivative.expiration_date: The restricted stock units were issued pursuant to the Plan. The restricted stock units shall vest in equal annual installments over 4 years from the date of grant, subject to continued service through such dates. Read SEC document |
| January 23, 2017 Filed Jan 24, 2017 21:31 UTC |
SOUTHWELL DAVID PDirector · President and CEO
|
GrantRestricted Stock Units · Derivative | 350,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-001845 · doc4.xml · derivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ITEK common stock. F2 · derivative.exercise_date: The restricted stock units were issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan (the "Plan") on December 13, 2016 and were amended on January 23, 2017 to modify their vesting schedule. The restricted stock units were modified so that instead of vesting based on the achievement of certain milestones, they will vest in equal annual installments over four years from the December 13, 2016 date of grant, subject to continued service through such dates. The amount in this column does not reflect the decrease in fair value as a result of the modification to the restricted stock units in 2017. F2 · derivative.expiration_date: The restricted stock units were issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan (the "Plan") on December 13, 2016 and were amended on January 23, 2017 to modify their vesting schedule. The restricted stock units were modified so that instead of vesting based on the achievement of certain milestones, they will vest in equal annual installments over four years from the December 13, 2016 date of grant, subject to continued service through such dates. The amount in this column does not reflect the decrease in fair value as a result of the modification to the restricted stock units in 2017. Read SEC document |
| January 23, 2017 Filed Jan 24, 2017 21:31 UTC |
Baumgartner Rudolf ASee Remarks
|
GrantRestricted Stock Units · Derivative | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-001844 · doc4.xml · derivative · entry 2 Baumgartner Rudolf A · CIK 0001632878 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ITEK common stock. F3 · derivative.exercise_date: The restricted stock units were issued pursuant to the Plan. The restricted stock units shall vest in equal annual installments over 4 years from the date of grant, subject to continued service through such dates. F3 · derivative.expiration_date: The restricted stock units were issued pursuant to the Plan. The restricted stock units shall vest in equal annual installments over 4 years from the date of grant, subject to continued service through such dates. Read SEC document |
| January 23, 2017 Filed Jan 24, 2017 21:31 UTC |
Baumgartner Rudolf ASee Remarks
|
GrantRestricted Stock Units · Derivative | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-001844 · doc4.xml · derivative · entry 1 Baumgartner Rudolf A · CIK 0001632878 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ITEK common stock. F2 · derivative.exercise_date: The restricted stock units were issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan (the "Plan") on December 13, 2016 and were amended on January 23, 2017 to modify their vesting schedule. The restricted stock units were modified so that instead of vesting based on the achievement of certain milestones, they will vest in equal annual installments over four years from the December 13, 2016 date of grant, subject to continued service through such dates. The amount in this column does not reflect the decrease in fair value as a result of the modification to the restricted stock units in 2017. F2 · derivative.expiration_date: The restricted stock units were issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan (the "Plan") on December 13, 2016 and were amended on January 23, 2017 to modify their vesting schedule. The restricted stock units were modified so that instead of vesting based on the achievement of certain milestones, they will vest in equal annual installments over four years from the December 13, 2016 date of grant, subject to continued service through such dates. The amount in this column does not reflect the decrease in fair value as a result of the modification to the restricted stock units in 2017. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:31 UTC |
RITTER DALEVice President, Finance
|
GrantRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-001543 · doc4.xml · derivative · entry 1 RITTER DALE · CIK 0001244154 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-01-16 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ITEK common stock. F2 · derivative.exercise_date: The restricted stock units were issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan (the "Plan"). The restricted stock units shall vest in equal 25% tranches every 6 months over a 2 year period from the date of grant, subject to continued service through such dates. Read SEC document |
| January 17, 2017 Filed Sep 18, 2017 20:35 UTC |
RITTER DALEVice President, Finance
|
Exercise / conversionRestricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-053158 · doc4.xml · derivative · entry 2 RITTER DALE · CIK 0001244154 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ITEK common stock. F2 · derivative.exercise_date: On September 14, 2017, 12,500 shares of Common Stock were issued in settlement of the restricted stock units described in footnote (4) below. F4 · derivative.exercise_date: The restricted stock units were issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan (the "Plan"). The restricted stock units vest in equal 25% tranches every 6 months over a 2 year period from the date of grant, subject to continued service through such dates. F2 · derivative.expiration_date: On September 14, 2017, 12,500 shares of Common Stock were issued in settlement of the restricted stock units described in footnote (4) below. F4 · derivative.expiration_date: The restricted stock units were issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan (the "Plan"). The restricted stock units vest in equal 25% tranches every 6 months over a 2 year period from the date of grant, subject to continued service through such dates. Read SEC document |
| January 06, 2017 Filed Jan 9, 2017 22:54 UTC |
SOUTHWELL DAVID PDirector · President and CEO
|
PurchaseCommon Stock | 60,000 | $1.75 | $105,000.00 |
DisclosureSEC source: 0000899243-17-000861 · doc4.xml · nonDerivative · entry 1 SOUTHWELL DAVID P · CIK 0001251553 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,765 F1 · acquired: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.749 to $1.75, inclusive. The reporting person undertakes to provide to Inotek Pharmaceuticals Corporation, any security holder of Inotek Pharmaceuticals Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · balance_after: Includes 2,765 shares of the Issuer's common stock acquired under the Issuer's Employee Stock Purchase Plan since the date of the Reporting Person's last Form 4 with Table I Information. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:03 UTC |
DEVON PARK BIOVENTURES LP10% owner
Devon Park Associates, L.P.10% owner
Devon Park Associates, LLC10% owner
|
OtherCommon Stock | 9,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-001008 · doc1.xml · nonDerivative · entry 2 DEVON PARK BIOVENTURES LP · CIK 0001356034 · 10% owner Devon Park Associates, L.P. · CIK 0001610919 · 10% owner Devon Park Associates, LLC · CIK 0001610920 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F3 · kind: Devon Park Associates, L.P. conducted an in-kind, pro rata distribution to its limited partners of all shares of the Issuer's common stock owned by it. F4 · ownership.nature: Represents the beneficial ownership of shares of the Issuer's common stock held directly by Devon Park Associates, L.P. Devon Park Associates, LLC is the general partner of Devon Park Associates, L.P. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:03 UTC |
DEVON PARK BIOVENTURES LP10% owner
Devon Park Associates, L.P.10% owner
Devon Park Associates, LLC10% owner
|
OtherCommon Stock | 3,243,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-001008 · doc1.xml · nonDerivative · entry 1 DEVON PARK BIOVENTURES LP · CIK 0001356034 · 10% owner Devon Park Associates, L.P. · CIK 0001610919 · 10% owner Devon Park Associates, LLC · CIK 0001610920 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,857 F1 · kind: Devon Park Bioventures, L.P. conducted an in-kind, pro rata distribution to its limited partners of all shares of the Issuer's common stock owned by it. F2 · ownership.nature: Represents the beneficial ownership of shares of the Issuer's common stock held directly by Devon Park Bioventures, L.P. Devon Park Associates, LLC is the general partner of Devon Park Associates, L.P., which is the general partner of Devon Park Bioventures, L.P. Read SEC document |
| September 28, 2016 Filed Sep 29, 2016 07:46 UTC |
BARBERICH TIMOTHY JDirector
|
GrantStock Options (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $9.49 | $0.00 |
DisclosureSEC source: 0000899243-16-030296 · doc4.xml · derivative · entry 1 BARBERICH TIMOTHY J · CIK 0001120355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2026-09-28 F1 · derivative.exercise_date: This stock option award was issued pursuant to Issuer's 2014 Stock Option and Incentive Plan and shall vest as follows: 25% of the shares shall be vested on September 28, 2017 and 1/36th of the remaining shares shall vest on each monthly anniversary thereafter, subject to Reporting Person's continued service as a director of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.